Latest news
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of "Moderate Buy" by Analysts - MarketBeatMarketBeat · Sat, 08 Aug 2026 06:47:15 GMTDenali Therapeutics (NASDAQ:DNLI) Stock Rating Upgraded by Wall Street Zen - MarketBeatMarketBeat · Sat, 08 Aug 2026 05:48:58 GMTDenali Therapeutics (DNLI) Is Up 7.9% After AVLAYAH Launch Drives First Full-Quarter Commercial Revenue - simplywall.stsimplywall.st · Sat, 08 Aug 2026 03:05:24 GMTDNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum - TradingViewTradingView · Fri, 07 Aug 2026 18:31:00 GMTDenali Therapeutics Inc. Stock 12‑Month Price Target Raised to $35.44, Implies 43% Upside - TradingViewTradingView · Fri, 07 Aug 2026 14:20:14 GMTDenali Therapeutics Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:DNLI) 2026-08-07 - Seeking AlphaSeeking Alpha · Fri, 07 Aug 2026 07:25:06 GMTDNLI 8-K & SEC Filings - Yahoo FinanceYahoo Finance · Fri, 07 Aug 2026 07:11:15 GMTDNLI 10-Q & SEC Filings - Yahoo FinanceYahoo Finance · Fri, 07 Aug 2026 04:01:18 GMT